Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 6Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 47Radiotherapy 37Fluorouracil 23Cetuximab 17pembrolizumab 11Carboplatin 11Paclitaxel 8Docetaxel 8Radiotherapy, Intensity-Modulated 6Chemotherapy, Adjuvant 6Surgical Procedures, Operative 5Standard of Care 5nimotuzumab 4Methotrexate 4Gabapentin 4Drug Therapy 4Afatinib 4Radiotherapy, Conformal 3Radiation 3Porfiromycin 3Nivolumab 3Neoadjuvant Therapy 3Fibroblast Growth Factor 7 3Bleomycin 3zalutumumab 2sargramostim 2epacadostat 2Tranexamic Acid 2Tirapazamine 2Pilocarpine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Head and Neck Neoplasms × epacadostat × Clear all
NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Incyte Corporation

Phase 3 Completed
89 enrolled 14 charts
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Incyte Corporation

Phase 3 Withdrawn
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡